Carolyn F. Deacon

Carolyn F. Deacon

Associate Professor


  1. 2013
  2. Published

    Is there a place for incretin therapies in obesity and prediabetes?

    Holst, Jens Juul & Deacon, Carolyn F., 13 Feb 2013, In : Trends in Endocrinology and Metabolism. 24, 3, p. 145-152 7 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Published

    The C-terminal extension of exendin-4 provides additional metabolic stability when added to GLP-1, while there is minimal effect of truncating exendin-4 in anaesthetized pigs

    Simonsen, L., Holst, Jens Juul, Madsen, K. & Deacon, Carolyn F., 10 Feb 2013, In : Regulatory Peptides. 181, 10, p. 17-21 5 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Published

    Glucagon-like peptides 1 and 2, enteroglucagon, glicentin and oxyntomodulin

    Holst, Jens Juul, Deacon, Carolyn F., Hartmann, Bolette & Pedersen, J., 2013, Handbook of Biologically Active Peptides . Kastin, AJ. (ed.). 2 ed. Elsevier, p. 1241-1250 10 p.

    Research output: Chapter in Book/Report/Conference proceedingBook chapterEducation

  5. Published

    Islet-cell dysfunction induced by glucocorticoid treatment: potential role for altered sympathovagal balance?

    van Raalte, D. H., Kwa, K. A. A., van Genugten, R. E., Tushuizen, M. E., Holst, Jens Juul, Deacon, Carolyn F., Karemaker, J. M., Heine, R. J., Mari, A. & Diamant, M., 2013, In : Metabolism. 62, 4, p. 568-577 10 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  6. 2012
  7. Published

    Linagliptin increases incretin levels, lowers glucagon, and improves glycemic control in type 2 diabetes mellitus

    Rauch, T., Graefe-Mody, U., Deacon, Carolyn F., Ring, A., Holst, Jens Juul, Woerle, H., Dugi, K. A. & Heise, T., Nov 2012, In : Diabetes Therapy. 3, 1, p. 10

    Research output: Contribution to journalJournal articleResearchpeer-review

  8. Published

    Commentary: Is endogenous GLP-1 the only important enhancer of glucose-induced insulin secretion in type 2 diabetes?

    Deacon, Carolyn F., 2012, In : Diabetes. 61, 9, p. 2219-2220

    Research output: Contribution to journalJournal articleResearchpeer-review

  9. Published

    Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes—a review and meta analysis

    Deacon, Carolyn F., Mannucci, E. & Ahren, B., 2012, In : Diabetes, Obesity and Metabolism Online. 14, 8, p. 762-767

    Research output: Contribution to journalReviewResearchpeer-review

  10. Published

    Impaired crosstalk between pulsatile insulin and glucagon secretion in prediabetic individuals

    Rohrer, S., Menge, B. A., Grüber, L., Deacon, Carolyn F., Schmidt, W. E., Veldhuis, J. D., Holst, Jens Juul & Meier, J. J., 2012, In : Journal of Clinical Endocrinology and Metabolism. 97, 5, p. E791-E795

    Research output: Contribution to journalJournal articleResearchpeer-review

  11. Published

    Linagliptin, a selective DPP-4 inhibitor, inhibits DPP-4, increases incretin levels, lowers glucagon, and improves glycaemic control in patients with Type 2 diabetes.

    Rauch, T., Graefe-Mody, U., Deacon, Carolyn F., Ring, A., Holst, Jens Juul, Woerle, H., Dugi, K. & Heise, T., 2012, In : Diabetes Therapy. 3, 1, p. 10

    Research output: Contribution to journalJournal articleResearchpeer-review

  12. Published

    Potential cardiovascular effects of incretin-based therapies

    Deacon, Carolyn F. & Marx, N., 2012, In : Expert Review of Cardiovascular Therapy. 10, p. 337-351

    Research output: Contribution to journalReviewResearchpeer-review

Previous 1...4 5 6 7 8 9 10 11 ...22 Next

ID: 9220